HK1104930A1 - Osteoprotegerin variant proteins - Google Patents
Osteoprotegerin variant proteinsInfo
- Publication number
- HK1104930A1 HK1104930A1 HK07110019.9A HK07110019A HK1104930A1 HK 1104930 A1 HK1104930 A1 HK 1104930A1 HK 07110019 A HK07110019 A HK 07110019A HK 1104930 A1 HK1104930 A1 HK 1104930A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bone
- gyps
- osteoprotegerin
- loss
- variant proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
The present invention relates to novel osteoprotegerin variant proteins (GYPs) that demonstrate reduced binding affinity for their ligand TRAIL when compared to wild-type osteoprotegerin. Nucleic acids which encode these GYPs are also provided. Recombinant vectors and host cells expressing these GYPs are also encompassed as are methods of producing recombinant GYPs. The present invention also relates to compositions comprising these GYPs, and to methods of treating bone diseases characterised by increased bone turnover and/or loss. The GYPs of the invention are useful for preventing bone resorption and may be used to treat any condition resulting in abnormal bone turnover or bone loss such as osteoporosis, hypercalcemia, Paget's disease of bone, multiple myeloma, bone cancer and bone loss due to rheumatoid arthritis or osteomyelitis, and the like.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63572204P | 2004-12-13 | 2004-12-13 | |
PCT/AU2005/001877 WO2006063390A1 (en) | 2004-12-13 | 2005-12-13 | Osteoprotegerin variant proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1104930A1 true HK1104930A1 (en) | 2008-01-25 |
Family
ID=36587448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07110019.9A HK1104930A1 (en) | 2004-12-13 | 2007-09-14 | Osteoprotegerin variant proteins |
Country Status (16)
Country | Link |
---|---|
US (2) | US7612169B2 (en) |
EP (1) | EP1824882B1 (en) |
JP (1) | JP4870683B2 (en) |
KR (1) | KR101250364B1 (en) |
CN (2) | CN102977205A (en) |
AT (1) | ATE544781T1 (en) |
AU (1) | AU2005316193B2 (en) |
BR (1) | BRPI0519008A2 (en) |
CA (1) | CA2587209A1 (en) |
ES (1) | ES2378456T3 (en) |
HK (1) | HK1104930A1 (en) |
IL (1) | IL183365A0 (en) |
MX (1) | MX2007007093A (en) |
NZ (1) | NZ554390A (en) |
WO (1) | WO2006063390A1 (en) |
ZA (1) | ZA200704473B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE544781T1 (en) * | 2004-12-13 | 2012-02-15 | Cephalon Australia Vic Pty Ltd | OSTEOPROTEGER INVARIANT PROTEINS |
US7943328B1 (en) | 2006-03-03 | 2011-05-17 | Prometheus Laboratories Inc. | Method and system for assisting in diagnosing irritable bowel syndrome |
US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
WO2008156865A2 (en) * | 2007-06-20 | 2008-12-24 | Schering Corporation | Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease |
US9333239B2 (en) | 2012-03-20 | 2016-05-10 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of osteoprotegerin (OPG) to increase human pancreatic beta cell survival and proliferation |
WO2014171827A1 (en) * | 2013-04-19 | 2014-10-23 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | A mutant tnfrsf11b (osteoprotegerin or opg) and uses thereof |
CN109306003B (en) * | 2017-07-28 | 2021-02-12 | 北京济全生物科技有限公司 | Mutant protein of osteoprotegerin, related product and application thereof |
CN109306002B (en) * | 2017-07-28 | 2021-02-12 | 北京济全生物科技有限公司 | N139 mutant protein of osteoprotegerin, and related product and application thereof |
CN109306004B (en) * | 2017-07-28 | 2020-12-15 | 北京济全生物科技有限公司 | S77 mutant protein of osteoprotegerin and related product and application thereof |
WO2024054566A1 (en) * | 2022-09-07 | 2024-03-14 | The Regents Of The University Of California | Treatment of cancer by blockade of osteoprotegerin |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US6613544B1 (en) * | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
US6369027B1 (en) * | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
US20030207827A1 (en) * | 1995-12-22 | 2003-11-06 | William J. Boyle | Osteoprotegerin |
US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
WO1998049305A1 (en) * | 1997-05-01 | 1998-11-05 | Amgen Inc. | Chimeric opg polypeptides |
US6087555A (en) * | 1997-10-15 | 2000-07-11 | Amgen Inc. | Mice lacking expression of osteoprotegerin |
US6562622B1 (en) | 1998-05-08 | 2003-05-13 | Diatech Pty, Ltd | Continuous in vitro evolution |
WO2001003719A2 (en) * | 1999-07-09 | 2001-01-18 | Amgen Inc. | Combination therapy for conditions leading to bone loss |
KR20010085996A (en) * | 1999-09-03 | 2001-09-07 | 스티븐 엠. 오드레 | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
US20030144187A1 (en) * | 1999-09-03 | 2003-07-31 | Colin R. Dunstan | Opg fusion protein compositions and methods |
CA2394536A1 (en) * | 1999-12-16 | 2001-06-21 | Amgen Inc. | Tnfr/opg-like molecules and uses thereof |
TWI318983B (en) * | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
DE10041084A1 (en) * | 2000-08-22 | 2002-03-14 | Infineon Technologies Ag | Method for forming a dielectric region in a semiconductor substrate |
EP1399555A2 (en) * | 2001-02-09 | 2004-03-24 | Maxygen Holdings Ltd. c/o Close Brothers (Cayman) Limited | Rank ligand-binding polypeptides |
EP1576088A4 (en) * | 2002-01-04 | 2006-09-06 | Xencor Inc | Dominant negative proteins and methods thereof |
EA007927B1 (en) * | 2002-04-10 | 2007-02-27 | Апплайд Резеч Системз Арс Холдинг Н. В. | Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
WO2004039995A1 (en) | 2002-11-01 | 2004-05-13 | Evogenix Pty Ltd | Mutagenesis methods using ribavirin and/or rna replicases |
ATE544781T1 (en) | 2004-12-13 | 2012-02-15 | Cephalon Australia Vic Pty Ltd | OSTEOPROTEGER INVARIANT PROTEINS |
-
2005
- 2005-12-13 AT AT05815463T patent/ATE544781T1/en active
- 2005-12-13 CN CN2012103379379A patent/CN102977205A/en active Pending
- 2005-12-13 JP JP2007544700A patent/JP4870683B2/en not_active Expired - Fee Related
- 2005-12-13 BR BRPI0519008-8A patent/BRPI0519008A2/en not_active IP Right Cessation
- 2005-12-13 WO PCT/AU2005/001877 patent/WO2006063390A1/en active Application Filing
- 2005-12-13 ES ES05815463T patent/ES2378456T3/en active Active
- 2005-12-13 NZ NZ554390A patent/NZ554390A/en not_active IP Right Cessation
- 2005-12-13 CN CN2005800407801A patent/CN101065401B/en not_active Expired - Fee Related
- 2005-12-13 ZA ZA200704473A patent/ZA200704473B/en unknown
- 2005-12-13 EP EP05815463A patent/EP1824882B1/en not_active Not-in-force
- 2005-12-13 US US11/303,169 patent/US7612169B2/en not_active Expired - Fee Related
- 2005-12-13 AU AU2005316193A patent/AU2005316193B2/en not_active Ceased
- 2005-12-13 KR KR1020077015835A patent/KR101250364B1/en not_active IP Right Cessation
- 2005-12-13 CA CA002587209A patent/CA2587209A1/en not_active Abandoned
- 2005-12-13 MX MX2007007093A patent/MX2007007093A/en active IP Right Grant
-
2007
- 2007-05-21 IL IL183365A patent/IL183365A0/en unknown
- 2007-09-14 HK HK07110019.9A patent/HK1104930A1/en not_active IP Right Cessation
-
2009
- 2009-09-11 US US12/584,802 patent/US8530624B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2587209A1 (en) | 2006-06-22 |
EP1824882A1 (en) | 2007-08-29 |
ES2378456T3 (en) | 2012-04-12 |
JP2008522593A (en) | 2008-07-03 |
US20100144600A1 (en) | 2010-06-10 |
CN101065401A (en) | 2007-10-31 |
US7612169B2 (en) | 2009-11-03 |
ZA200704473B (en) | 2008-09-25 |
AU2005316193A1 (en) | 2006-06-22 |
WO2006063390A1 (en) | 2006-06-22 |
IL183365A0 (en) | 2007-09-20 |
KR101250364B1 (en) | 2013-04-05 |
CN102977205A (en) | 2013-03-20 |
EP1824882B1 (en) | 2012-02-08 |
NZ554390A (en) | 2010-07-30 |
JP4870683B2 (en) | 2012-02-08 |
BRPI0519008A2 (en) | 2008-12-23 |
CN101065401B (en) | 2012-10-24 |
AU2005316193B2 (en) | 2012-05-17 |
US8530624B2 (en) | 2013-09-10 |
KR20070091648A (en) | 2007-09-11 |
US20060189528A1 (en) | 2006-08-24 |
ATE544781T1 (en) | 2012-02-15 |
MX2007007093A (en) | 2007-12-07 |
EP1824882A4 (en) | 2008-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1104930A1 (en) | Osteoprotegerin variant proteins | |
WO2003016468A3 (en) | Antagonistic anti-htnfsf13b human antibodies | |
MX348154B (en) | IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF. | |
WO2005005604A3 (en) | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses | |
WO2002057664A3 (en) | Bacillus thuringiensis insecticidal proteins | |
GEP20166454B (en) | Sclerostin binding agents | |
WO2002102993A3 (en) | Human secreted proteins | |
WO2003016475A3 (en) | Nucleic acid and amino acid sequences involved in pain | |
WO2001047952A3 (en) | Insecticidal proteins from bacillus thuringiensis | |
TW200716745A (en) | Anti-TNF antibodies, compositions, methods and uses | |
IL210392A0 (en) | Antibodies that bind to tgf-?? binding proteins with an affinity of 106m-1 and uses thereof | |
WO2002072788A3 (en) | Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses | |
AU1153902A (en) | Nogo receptor homologs | |
WO2003031462A3 (en) | Nogo receptor-mediated blockade of axonal growth | |
WO2001055308A3 (en) | Nucleic acids, proteins, and antibodies | |
WO1999053040A3 (en) | Human nucleic acid sequences from ovarian tumour tissue | |
WO2001098491A3 (en) | Osteolevin gene polymorphisms | |
WO2002092787A3 (en) | Human secreted proteins | |
WO2001003719A3 (en) | Combination therapy for conditions leading to bone loss | |
AU2002303214A1 (en) | Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof | |
WO2007087053A3 (en) | Bmp-7 variant compositions, methods and uses | |
WO2004094651A3 (en) | Novel human polypeptides encoded by polynucleotides | |
WO2003014297A3 (en) | Compositions and methods relating to the daptomycin biosynthetic gene cluster | |
WO2007024668A3 (en) | Targeting of herpes simplex virus to specific receptors | |
WO2001072826A3 (en) | Oncogenic osteomalacia-related gene 1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20151213 |